THREE-DIMENSIONAL IMAGING OF TUMORS THROUGH TISSUE

Information

  • Research Project
  • 3493282
  • ApplicationId
    3493282
  • Core Project Number
    R43CA059072
  • Full Project Number
    1R43CA059072-01
  • Serial Number
    59072
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/1/1993 - 31 years ago
  • Project End Date
    4/30/1994 - 30 years ago
  • Program Officer Name
  • Budget Start Date
    4/1/1993 - 31 years ago
  • Budget End Date
    4/30/1994 - 30 years ago
  • Fiscal Year
    1993
  • Support Year
    1
  • Suffix
  • Award Notice Date
    3/16/1993 - 31 years ago
Organizations

THREE-DIMENSIONAL IMAGING OF TUMORS THROUGH TISSUE

We propose to apply a new, non-invasive, non-contacting technique, Laser Heterodyne Imaging (LHI) to 3-dimensional imaging of neoplasms. Preliminary measurements have been made through ~1mm of mouse skin and in 1.4mm phantoms, using dyes similar to those used in PDT. With improved apparatus, our goal is several centimeters penetration. LHI measures intensity-modulated fluorescence originating from the heterodyning of two laser beams in a small intersection volume, thus permitting localized measurement. That fluorescence is modulated at the difference frequency of the two beams (40MHz). Heterodyning discriminates against interfering background fluorescence, thus permitting measurements at depth, even through highly turbid biological tissue. LHI can enhance the diagnostic capabilities of Laser Induced Fluorescence by determining tumor boundaries in three dimensions. Our specific aims are (1) to compare the capabilities of LHI with established clinical techniques through a graded set of experiments (using animal tissue in vitro and in vivo and concluding with an animal model for basal cell carcinoma), (2) to investigate the effect of scattering on performance (attainable depth), (3) to investigate the possibility of using endogenous fluorescent agents, and (4) to define a Phase 2 prototype to measure skin cancer and deeper-seated soft tissue neoplasms, like breast cancer, in human subjects.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    MEDISPECTRA, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    LEXINGTON
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02421
  • Organization District
    UNITED STATES